MD+DI Online is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Ancora Heart Enrolls 1st Patient in CORCINCH-HF Trial

JohanSwanepoel - stock.adobe.com IMG_Jan282021at22143PM.jpg
Ancora Heart has enrolled the first patient in the CORCINCH-HF pivotal trial. The study is designed to evaluate the safety and efficacy of the AccuCinch Ventricular Restoration System in patients who have symptomatic heart failure with reduced ejection fraction (HFrEF).

Ancora Heart has enrolled the first patient in the CORCINCH-HF pivotal trial. The study is designed to evaluate the safety and efficacy of the AccuCinch Ventricular Restoration System in patients who have symptomatic heart failure with reduced ejection fraction (HFrEF).

The Santa Clara, CA-based company won approval for a pivotal study of the device in June of 2020.

CORCINCH-HF is designed to enroll 400 patients at up to 80 centers worldwide. The study has a design allowing initial analysis of safety and clinical efficacy for PMA submission after the first 250 patients have reached six months of follow-up, and then a second analysis after the entire cohort has reached 12 months of follow-up.

During the AccuCinch procedure, an implant is placed into the mid-left ventricular wall, the implant is then cinched. Once cinched, the implant is intended to reduce the size of the left ventricle, as well as support and strengthen the heart wall to help improve left ventricular function. The AccuCinch System is designed to provide extra stability and support to the left ventricular wall. This may lower stress on the heart and allow improved functional capacity and quality of life for patients.

“Previously collected data on early feasibility implants suggests that the AccuCinch System may afford significant clinical benefits to patients suffering from heart failure with reduced ejection fraction,” Jeff Closs, president and CEO of Ancora Heart, said in a release. “We anticipate that the data from this study will confirm and expand upon these early findings and enable us to ultimately provide an important innovation that may halt or even reverse the progression of heart failure in many patients.”

Hide comments
account-default-image

Comments

  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Publish